**Name of Journal:** *World Journal of Clinical Cases*

**Manuscript NO:** 76679

**Manuscript Type:** CASE REPORT

**Early-onset ophthalmoplegia, cervical dyskinesia, and lower extremity weakness due to partial deletion of chromosome 16: A case report**

Xu M *et al.* Ophthalmoplegia from chromosome 16 partial deletion

Min Xu, Jiao Jiang, Yan He, Wei-Yue Gu, Bo Jin

**Min Xu, Jiao Jiang, Yan He, Bo Jin,** Department of Neurology, Children’s Hospital of Nanjing Medical University, Nanjing 210008, Jiangsu Province, China

**Wei-Yue Gu,** Chigene (Beijing), Translational Medical Research Center Co. Ltd, Beijing 101111, China

**Author contributions:** Xu M and Jin B designed the research study; Jiang J and He Y performed the research; Jiang J and Gu WY contributed new reagents and analytic tools; Xu M and He Y analyzed the data and wrote the manuscript; All authors have read and approved the final manuscript.

**Corresponding author: Bo Jin, MD, Chief Doctor,** Department of Neurology, Children’s Hospital of Nanjing Medical University, No. 72 Guangzhou Road, Gulou District, Nanjing 210008, Jiangsu Province, China. 13182852157@163.com

**Received:** March 25, 2022

**Revised:** June 8, 2022

**Accepted:** July 21, 2022

**Published online:**

**Abstract**

BACKGROUND

We explored the genotype-phenotype correlation of the novel deletion 16p13.2p12.3 in an 8-year-old child with progressive total ophthalmoplegia, cervical dyskinesia, and lower limb weakness by comparing the patient’s clinical features with previously reported data on adjacent copy number variation (CNV) regions.

CASE SUMMARY

Specifically, we first performed whole-exome sequencing, CNV-sequencing, and mitochondrial genome sequencing on the patient and his parents, then applied “MitoExome” (the entire mitochondrial genome and exons of nuclear genes encoding the mitochondrial proteome) analysis to screen for genetic mitochondrial diseases.We identified a *de novo* 7.23 Mb deletion, covering 16p13.2p12.3, by both whole-exome sequencing and CNV sequencing. We also detected 16p13.11 in the deleted region, which is the recurrent distinct region associated with neurodevelopmental disorder. However, the patient only displayed features of progressive total ophthalmoplegia, cervical dyskinesia, and weakness in his lower limbs without neurodevelopmental disorder. The “MitoExome” sequencing was negative. Brain magnetic resonance imaging revealed non-specific sporadic changes in the occipital parietal lobe and basal ganglia.

CONCLUSION

Taken together,these results indicated that 16p13.2p12.3 deletion causes a syndrome with the phenotype of early-onset total ophthalmoplegia. The “MitoExome” analysis is powerful for the differential diagnosis of mitochondrial diseases. We report a novel copy number variant in this case, but further confirmation is required.

**Key Words:** Cervical dyskinesia; Copy number variation; Lower limbs weakness; Ophthalmoplegia; Whole-exome sequencing; Case report

Xu M, Jiang J, He Y, Gu WY, Jin B. Early-onset ophthalmoplegia, cervical dyskinesia, and lower extremity weakness due to partial deletion of chromosome16: A case report. *World J Clin Cases* 2022; In press

**Core Tip:** At present, little is known about the associated phenotypes of copy number variations in the short arm of chromosome 16. The most remarkable copy number variations is 16p13.11 microdeletion/microduplication. The main clinical features of this syndrome are a series of neurological abnormalities such as mental retardation, autism, schizophrenia, epilepsy, and attention deficit hyperactivity disorder. We identified a de novo 7.23 Mb deletion, covering 16p13.2p12.3. 16p13.11 was included in the deleted region, which is the recurrent distinct region associated with neurodevelopmental disorder. However, the patient only displayed features of progressive total ophthalmoplegia, cervical dyskinesia, and weakness in the lower limbs without neurodevelopmental disorder.

**INTRODUCTION**

At present, little is known regarding the associated phenotypes of copy number variations (CNV) in the short arm of chromosome 16. The most remarkable CNV is 16p13.11 microdeletion/microduplication. Notably, nuclear distribution gene E homolog 1 and N-terminal asparagine amidase genes located in 16p13.11 region have been associated with a series of neurological abnormalities, such as intellectual disabilities, autism, schizophrenia, epilepsy, and attention-deficit hyperactivity disorder in patients with this syndrome[1,2]. The adjacent regions of 16p13.11, chromosome 16p13.3 deletion causes a syndrome, which is characterized as failure to thrive, hypotonia, short stature, microcephaly, characteristic facial features, mild to moderate intellectual disability, organ anomalies, and vulnerability to infections[3]. Previous studies have shown that chromosome 16p11.2 locus, the other neighboring region characterized by recurrent CNVs, is the chromosomal region related to Autistic Spectrum Disorder[4,5]. It seems that 16p13 and its adjacent regions are highly suspected sites associated with a series of neuropsychiatric disorders. Primary or secondary causes of internal ophthalmoplegia usually indicate a central nervous system situation. For example, patients with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome may display primary encephalopathy, including ptosis (external ophthalmoplegia) with internal ophthalmoplegia[6]. Notably, mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes syndrome is caused by mitochondrial DNA mutations, while mitochondrial variations have been attributed to occurrence of diseases of Kearns-Sayre syndrome (KSS), which is associated with early-onset ophthalmoplegia[7,8].

**CASE PRESENTATION**

***Chief complaints***

The patient was an 8-year-old boy, who presented with gradually progressive unilateral ptosis at the age of 6 years, which developed to bilateral ptosis at 8 years and 4 mo.

***History of present illness***

The patient was an 8-year-old boy with bilateral ptosis.

***History of past illness***

At the end of December 2017, the patient developed a fever of unknown origin, with his body temperature found to be as high as 38.5 °C. He recovered after being given oral antipyretics. One week after the fever, the patient had a stroke of dyskinesia and kept tilting his head to the left (cervical dyskinesia), a phenomenon that was accompanied by eye movement disorders.

***Personal and family history***

The patient was the first child born to non-consanguineous parents, and there are no similarly affected family members. Although he had a “history of congenital heart disease,” subsequent cardiac color Doppler ultrasound examination revealed normal results. The patient had no developmental milestone delays.

***Physical examination***

Physical examination revealed that he had bilateral upper eyelid dropping (50% pupils covered). Moreover, he had limited abduction in the right eye, neck dystonia, and slightly reduced (degree 5-) muscle strength in bilateral lower limbs, while his bilateral knee reflexes disappeared. He also exhibited right cryptorchidism and a small penis. He could neither squat nor jump on one foot.

***Laboratory examinations***

Blood tests showed unremarkable results. Notably, he had a blood acetylcholine receptor antibody level of 0.82 nmol/L, while IgG tests for anti-MuSK, anti-Titin antibody, and human low-density lipoprotein receptor-related protein 4 were negative.

***Imaging examinations***

Brain magnetic resonance imaging revealed diffused signals in the occipital, parietal cortex, and basal ganglia(Figure 1). His right ptosis was better, although it did not disappear after treatment with prednisone, neostigmine, and omeprazole from January 2018 to October 2019. His eye lid dropping reappeared in March 2020 and progressed to be bilateral. In August 2019, he was hospitalized due to a recurrent headache and was unresponsive to mannitol and carbamazepine. The patient was currently in the first grade of elementary school with medium grades.

***Whole-exome sequencing***

Whole exome libraries were prepared using the xGen Exome Research Panel v1.0 (IDT, Iowa, United States) and sequenced on the Novaseq 6000 platform (Illumina, San Diego, CA, United States). Raw data were cleaned using the fastp software package. Subsequently, the paired-end reads were performed using Burrows-Wheeler Aligner to the Ensemble GRCh37/hg19 reference genome. Synonymous and short indel calling were conducted using GATK software package followed by ANNOVAR annotation. Prediction was performed using the Provean, Sift, Polypen2\_hdiv, Polypen2\_hvar, Mutationtaster, M-Cap, and Revel software packages. The pathogenicity of all the variants was interpretated according to the guidelines of the American College of Medical Genetics and Genomics.

***CNV sequencing***

We performed CNV-sequencing[9], a CNV detection method based on high-throughput sequencing, in the patient. Briefly, genomic DNA was first sheared to 200-300 bp fragments *via* sonication, then subjected to quality control *via* electrophoresis. Ends of DNA fragments were patched using a DNA repair enzyme system to generate blunt ends, then a single adenine nucleotide was added to the 3’ end to form an overhanging A-tail. Subsequently, the genome was amplified by ligation-mediated PCR for 4-6 cycles. We used the same sequencing platform and data cleaning protocols to detect CNVs with a length of 100 kB and above using Chigene independently developed software packages. After that, we employed Decipher, ClinVar, OMIM, DGV, and ClinGen for annotation.

***High-sensitive mitochondrial DNA sequencing***

At least 2 mL peripheral blood was collected from the patient, and mitochondrial DNA was extracted using the mitochondrial DNA extraction kit. Full-length mitochondrial DNA was amplified and purified *via* PCR, using the high-fidelity DNA polymerase and visualized *via* agarose gel electrophoresis. Paired-ended 150 bp sequencing was performed on the Novaseq6000 sequencing system. The sequenced data was aligned to reference sequence of NC\_012920 (human complete mitochondrial genome 16569 bp circular DNA) using the Burrows-Wheeler Aligner software. The variants were then mapped onto the MITOMAP database, while pathogenicity was performed according to the MITOtip.

***Gene testing results***

Whole-exome sequencing sequencing results revealed no suspected disease-causing variants. Next, we employed the CNV analysis method (developed by Chigene) on whole-exome sequencing data and found that two deletions of the neighboring region of Chr16:15,125,591-16326688 (approximately 1.20 Mb) and 9857005-14989502 (approximately 5.13 Mb). CNV sequencing data revealed *de novo* heterozygous deletion of chr16:9699585-16928372 (approximately 7.23 Mb) (Figure 2). Next, we compared this region and central nervous system phenotype with Decipher patients previously documented (Figure 3). Genes related to *OMIM* disorders are listed in Table 1. The mitochondrial DNA sequencing revealed negative results.

**FINAL DIAGNOSIS**

A *de novo* heterozygous deletion of chr16:9699585-16928372 (approximately 7.23 Mb) was identified. Due to this deletion on chromosome 16, the patient has early-onset ophthalmoplegia, cervical dyskinesia, and lower extremity weakness.

**TREATMENT**

Since the patient showed elevated anti-acetylcholine receptor antibody levels, treatment with glucocorticoids and an acetylcholinesterase inhibitor were used.

**OUTCOME AND FOLLOW-UP**

The treatment effect was successful.

**DISCUSSION**

Ophthalmoplegia cases are characterized by central neurological, muscular, and synaptic abnormalities. In the present case, the evidence of the stroke-like onset of internal ophthalmoplegia and cervical dyskinesia and brain magnetic resonance imaging findings revealed a central nervous system disorder. Ophthalmoplegia is usually caused by damage to the midbrain. This patient’s magnetic resonance imaging revealed no abnormal signals in his midbrain and middle cranial fossa. In the patient’s anamnesis, we originally considered ophthalmoplegic migraine or recurrent ophthalmoplegic neuropathy, a rare condition manifesting as episodes of ipsilateral headache followed by ocular cranial nerves palsy, owing to his unexplained headache during the treatment. However, previous studies have shown that ophthalmoplegia typically persists for weeks to months and was reversible in patients with ophthalmoplegic migraine/recurrent ophthalmoplegic neuropathy[10,11]. Since the patient displayed elevated anti-acetylcholine receptor antibody levels and responded well to treatment using glucocorticoid and acetylcholinesterase inhibitor, myasthenia gravis (MG) was also the candidate diagnosis. However, MG failed to explain the early and urgent pattern of onset as well as the brain changes.

Mitochondrial diseases characterized by ocular symptoms include chronic progressive external ophthalmoplegia and KSS. Chronic progressive external ophthalmoplegia is a relatively mild mitochondrial disease characterized by extraocular muscle weakness and ptosis, often with weakness in the extremities[12]. Ptosis usually progresses to ophthalmoplegia over months or years. KSS was defined as chronic progressive external ophthalmoplegia initiated before age 20 with retinopathy of pigmentation and associated with at least one of the following: cardiac conduction disturbances, cerebellar ataxia, or elevated cerebrospinal fluid protein concentrations[13]. KSS, mitochondrial cytopathy due to mitochondrial CNV[14], could explain the early-onset, progressive external ophthalmoplegia, and suspected cardiomyopathy. However, analysis revealed negative results.

Our patient exhibited different clinical features from the previously reported cases of chromosome 16p CNVs. As far as we know, CNVs in chromosome 16p, including the proximal 16p11.2 deletion/duplication, intermedia 16p13.11 microdeletion/microduplication, and terminal 16p13.3 deletion, have been strongly associated with neurodevelopmental and/or neuropsychiatric disorders[1-5]. Moreover, Redaelli *et al*[14] identified four smallest regions of overlapping, one located in 16p13.11, one located in at 16p12.2, and two close smallest regions of overlapping occurring in 16p11.2. Based on the results of 27 CNVs in chromosome 16, the authors concluded that developmental delay in those patients was caused by recurrent non-allelic homologous recombination in chromosome 16[15]. Notably, the CNV in our patient resulted from full-length deletion of 16p13.11, while it is supposed to be associated with signs of 16p13.11 microdeletion syndrome, that is developmental delay, microcephaly, epilepsy, short stature, facial dysmorphism, and behavioral problems. However, we found none of these signs in our patient. Identification of the novel pathogenic CNV in our patient was inconclusive, according to the documented cases and OMIM genes (Table 1).

**CONCLUSION**

In conclusion, we identified a CNV heterozygous deletion in the 16p region in a Chinese patient with premature ophthalmoplegia, cervical spine dyskinesia, and lower extremity weakness through whole-exome sequencing, CNV sequencing, and MitoExome analysis strategies. MitoExome analysis is critical for differential diagnosis of mitochondrial diseases. Particularly, ptosis, ophthalmoplegia, and proximal muscle weakness are common occurrences in both mitochondrial diseases (MDs) and MG, which strongly indicate neuromuscular junction (NMJ) disorders. Generally, clinical grounds alone cannot effectively distinguish MDs and MG in patients with NMJ dysfunction[16,17]. Since NMJ abnormalities are common in MDs, there is need to perform MD-associated genetic tests. We recommend that “MitoExome” analysis should be applied in patients with an ambiguous diagnosis of NMJ disorders.

**REFERENCES**

1 **Ramalingam A**, Zhou XG, Fiedler SD, Brawner SJ, Joyce JM, Liu HY, Yu S. 16p13.11 duplication is a risk factor for a wide spectrum of neuropsychiatric disorders. *J Hum Genet* 2011; **56**: 541-544 [PMID: 21614007 DOI: 10.1038/jhg.2011.42]

2 **Tropeano M,** Andrieux J, Collier DA. Clinical utility gene card for: 16p13.11 microdeletion syndrome. Eur J Hum Genet 2014;22 [PMID: 24105370 DOI: 10.1038/ejhg.2013.230]

3 **Bartsch O**, Rasi S, Delicado A, Dyack S, Neumann LM, Seemanová E, Volleth M, Haaf T, Kalscheuer VM. Evidence for a new contiguous gene syndrome, the chromosome 16p13.3 deletion syndrome alias severe Rubinstein-Taybi syndrome. *Hum Genet* 2006; **120**: 179-186 [PMID: 16783566 DOI: 10.1007/s00439-006-0215-0]

4 **Taylor CM**, Smith R, Lehman C, Mitchel MW, Singer K, Weaver WC, Chung W. 16p11.2 Recurrent Deletion. 2009 Sep 22. In: GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993– [PMID: 20301775]

5 **Niarchou M**, Chawner SJRA, Doherty JL, Maillard AM, Jacquemont S, Chung WK, Green-Snyder L, Bernier RA, Goin-Kochel RP, Hanson E, Linden DEJ, Linden SC, Raymond FL, Skuse D, Hall J, Owen MJ, Bree MBMVD. Psychiatric disorders in children with 16p11.2 deletion and duplication. *Transl Psychiatry* 2019; **9**: 8 [PMID: 30664628 DOI: 10.1038/s41398-018-0339-8]

6 **Malfatti E**, Laforêt P, Jardel C, Stojkovic T, Behin A, Eymard B, Lombès A, Benmalek A, Bécane HM, Berber N, Meune C, Duboc D, Wahbi K. High risk of severe cardiac adverse events in patients with mitochondrial m.3243A>G mutation. *Neurology* 2013; **80**: 100-105 [PMID: 23243073 DOI: 10.1212/WNL.0b013e31827b1a2f]

7 **Barshop BA**, Nyhan WL, Naviaux RK, McGowan KA, Friedlander M, Haas RH. Kearns-Sayre syndrome presenting as 2-oxoadipic aciduria. *Mol Genet Metab* 2000; **69**: 64-68 [PMID: 10655159 DOI: 10.1006/mgme.1999.2946]

8 **Puoti G**, Carrara F, Sampaolo S, De Caro M, Vincitorio CM, Invernizzi F, Zeviani M. Identical large scale rearrangement of mitochondrial DNA causes Kearns-Sayre syndrome in a mother and her son. *J Med Genet* 2003; **40**: 858-863 [PMID: 14627683 DOI: 10.1136/jmg.40.11.858]

9 **Xie C**, Tammi MT. CNV-seq, a new method to detect copy number variation using high-throughput sequencing. *BMC Bioinformatics* 2009; **10**: 80 [PMID: 19267900 DOI: 10.1186/1471-2105-10-80]

10 **Gelfand AA**, Gelfand JM, Prabakhar P, Goadsby PJ. Ophthalmoplegic "migraine" or recurrent ophthalmoplegic cranial neuropathy: new cases and a systematic review. *J Child Neurol* 2012; **27**: 759-766 [PMID: 22241707 DOI: 10.1177/0883073811426502]

11 **López-Gallardo E**, López-Pérez MJ, Montoya J, Ruiz-Pesini E. CPEO and KSS differ in the percentage and location of the mtDNA deletion. *Mitochondrion* 2009; **9**: 314-317 [PMID: 19410662 DOI: 10.1016/j.mito.2009.04.005]

12 **Heidenreich JO**, Klopstock T, Schirmer T, Saemann P, Mueller-Felber W, Auer DP. Chronic progressive external ophthalmoplegia: MR spectroscopy and MR diffusion studies in the brain. *AJR Am J Roentgenol* 2006; **187**: 820-824 [PMID: 16928952 DOI: 10.2214/AJR.05.0180]

13 **Remes AM**, Peuhkurinen KJ, Herva R, Majamaa K, Hassinen IE. Kearns-Sayre syndrome case presenting a mitochondrial DNA deletion with unusual direct repeats and a rudimentary RNAase mitochondrial ribonucleotide processing target sequence. *Genomics* 1993; **16**: 256-258 [PMID: 7683627 DOI: 10.1006/geno.1993.1170]

14 **Redaelli S**, Maitz S, Crosti F, Sala E, Villa N, Spaccini L, Selicorni A, Rigoldi M, Conconi D, Dalprà L, Roversi G, Bentivegna A. Refining the Phenotype of Recurrent Rearrangements of Chromosome 16. *Int J Mol Sci* 2019; **20** [PMID: 30836598 DOI: 10.3390/ijms20051095]

15 **Ben Yaou R**, Laforêt P, Bécane HM, Jardel C, Sternberg D, Lombès A, Eymard B. [Misdiagnosis of mitochondrial myopathies: a study of 12 thymectomized patients]. *Rev Neurol (Paris)* 2006; **162**: 339-346 [PMID: 16585889 DOI: 10.1016/s0035-3787(06)75020-2]

16 **Whittaker RG**, Schaefer AM, Taylor RW, Turnbull DM. Differential diagnosis in ptosis and ophthalmoplegia: mitochondrial disease or myasthenia? *J Neurol* 2007; **254**: 1138-1139 [PMID: 17361341 DOI: 10.1007/s00415-006-0484-5]

17 **Braz LP**, Ng YS, Gorman GS, Schaefer AM, McFarland R, Taylor RW, Turnbull DM, Whittaker RG. Neuromuscular Junction Abnormalities in Mitochondrial Disease: An Observational Cohort Study. *Neurol Clin Pract* 2021; **11**: 97-104 [PMID: 33842062 DOI: 10.1212/CPJ.0000000000000795]

**Footnotes**

**Informed consent statement:** Informed written consent was obtained from the patient for publication of this report and any accompanying images.

**Conflict-of-interest statement:** The authors declare that they have no conflict of interest.

**CARE Checklist (2016) statement:** The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** March 25, 2022

**First decision:** May 30, 2022

**Article in press:**

**Specialty type:** Genetics and heredity

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): A, A

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): 0


Grade E (Poor): 0

**P-Reviewer:** Ozden F, Turkey; Sharaf MM, Syria **S-Editor:** Wand DM **L-Editor:** Filipodia A **P-Editor:** Wang DM


**Figure Legends**



**Figure 1 Brain magnetic resonance imaging showed diffused short T1/long T2 signals in the occipital, parietal cortex, and basal ganglia area.** No significant findings in midbrain.



**Figure 2 *De novo* heterozygous 16p13.2p12.3 deletion detected by copy number variation sequencing.**



**Figure 3 Comparison of copy number variations and central nervous system or neuropsychiatric disorders in this study and documented Decipher patients.** Red boxes show the regions of heterozygous deletions. The genome coordinates had been lifted over from GRCh37 to GRCh38. DD: Developmental delay; GDD: Global developmental delay; ID: Intellectual disability.

**Table 1** **Deleted *OMIM* genes in the 16p13.2p12.3 region**

|  |  |  |
| --- | --- | --- |
| **Gene** | **Disorder** | **Inheritance** |
| *ABCC1* | Deafness, autosomal dominant 77 (?) | AD |
| *ABCC6* | Arterial calcification, generalized, of infancy, 2 | AR |
| *ABCC6* | Pseudoxanthoma elasticum | AR |
| *ABCC6* | Pseudoxanthoma elasticum, forme fruste | AD |
| *CIITA* | Rheumatoid arthritis, susceptibility to |  |
| *CIITA* | Bare lymphocyte syndrome, type II, complementation group A | AR |
| *EMP2* | Nephrotic syndrome, type 10 | AR |
| *ERCC4* | XFE progeroid syndrome | AR |
| *ERCC4* | Fanconi anemia, complementation group Q | AR |
| *ERCC4* | Xeroderma pigmentosum, type F/Cockayne syndrome | AR |
| *GRIN2A* | Epilepsy, focal, with speech disorder and with or without mental retardation | AD, ADIP |
| *LITAF* | Charcot-Marie-Tooth disease, type 1C | AD, H |
| *MYH11* | Megacystis-microcolon-intestinal hypoperistalsis syndrome 2 | AR |
| *MYH11* | Aortic aneurysm, familial thoracic 4 | AD |
| *MYH11* | Visceral myopathy 2 | AD |
| *NDE1* | Microhydranencephaly (?) | AR |
| *NDE1* | Lissencephaly 4 (with microcephaly) | AR |
| *PARN* | Dyskeratosis congenita, autosomal recessive 6 | AR |
| *PARN* | Pulmonary fibrosis and/or bone marrow failure, telomere-related, 4 | AD, ADIP |
| *TAT* | Tyrosinemia, type II | AR |
| *YY1AP1* | Grange syndrome | AR |

Sign “?” indicates that more solid evidence is needed. AD: Autosomal dominant; ADIP: Autosomal dominant with incomplete penetrance; AR: Autosomal recessive.